Nevro Reports First-Quarter 2024 Financial Results
Nevro Corp. reported its first-quarter 2024 financial results along with additional restructuring steps to boost profitability. The company raised its adjusted EBITDA guidance, reaffirmed revenue guidance for 2024, and promoted Christofer Christoforou to COO. Revenue grew to $101.9 million, with a net loss from operations of $35.8 million and adjusted EBITDA loss of $9.6 million. The company's improved gross margin, operating expenses, and cash position were highlighted. Full-year revenue guidance stands at $435 million to $445 million, with adjusted EBITDA guidance revised to a range of negative $5 million to positive $2 million for 2024.
Nevro raised its adjusted EBITDA guidance and reaffirmed revenue guidance for full-year 2024, showcasing a positive outlook for profitability and growth.
The promotion of Christofer Christoforou to Chief Operating Officer reflects the company's commitment to driving operational efficiencies and innovative therapies for chronic pain.
Nevro's first-quarter 2024 financial results highlighted revenue growth, improved gross margin, and disciplined expense management efforts, positioning the company for continued success.
The net loss from operations of $35.8 million and adjusted EBITDA loss of $9.6 million for the first quarter of 2024 could raise concerns about profitability and financial performance.
Restructuring charges of $5.5 million and expenses related to the Vyrsa acquisition could impact Nevro's financials and cash position in the short term.
Lower U.S. trial procedures and ongoing litigation-related legal expenses may pose challenges to Nevro's business operations and financial health.
Insights
Upon reviewing the financial performance of Nevro, several key points emerge. The reported worldwide revenue increase of 5.8% is a positive sign, demonstrating modest growth year-over-year. However, it is important to note that U.S. trial procedures have seen a decrease of approximately 5.1%, which could potentially raise concerns about future revenue growth and market penetration.
The announcement of an improved adjusted EBITDA guidance, moving from a projected loss to a potential gain, indicates a positive trajectory towards profitability. Nevertheless, investors should be cautious about the net loss from operations of $35.8 million, which even when excluding one-time charges, still stands at a significant $26.1 million loss. The increase in gross margin, driven by a shift to higher margin products, is indeed a positive development and speaks to the company's efficiency and product mix strategy.
Furthermore, the cash position has seen a decrease, which should be monitored closely, as liquidity is important for ongoing operations and R&D investments. The expected restructuring charges in the second quarter may also weigh on the financials short term, but are aimed at long-term efficiency gains.
In the context of the medical device industry, Nevro's focus on expanding its sacroiliac joint (SI) joint business and training physicians on its Nevro1™ system is an indicator of strategic market expansion. The enrollment in the PDN Clinical Sensory Study outpacing expectations could signal strong market interest and potential for future product adoption. However, the pause in enrollment might raise questions regarding the immediate commercialization timeline.
It’s also worth noting the competitive landscape in which Nevro operates. With a flat performance in U.S. permanent implant procedures, it is important to observe how the company differentiates itself from competitors and whether its investments in R&D and training will translate into increased market share.
For investors, the company's ability to leverage recent FDA clearances and its continued investment in innovation are positive signs, but the balance between R&D expenditure and operational efficiency will be key to sustainable growth.
Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability
Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024
Promotes Christofer Christoforou to Chief Operating Officer
"We are pleased with our first quarter performance which demonstrates our continued focus on executing our three-pillar strategy of commercial execution, market penetration and profit progress. Worldwide revenue and adjusted EBITDA both came in ahead of our expectations," said Kevin Thornal, Nevro's CEO and President. "In addition, we are excited with the progress we are making on ramping up our nascent sacroiliac joint business, with more than 220 physicians trained thus far on Nevro1™, one of our three SI joint products."
Thornal continued, "Based on our first quarter performance, the additional restructuring steps we are taking to make Nevro a stronger and healthier company, and our outlook for the remainder of this year, we are raising our adjusted EBITDA guidance to a range of a loss of
"Also, I'm thrilled that Chris is stepping into the Chief Operating Officer role. He has been with Nevro for eight years and is a valuable member of our leadership team. Chris' experience, skillset and strong track record of success will be instrumental as we drive further operational efficiencies, expand margins and continue to focus on delivering innovative treatment therapies for patients suffering from chronic pain," Thornal added.
First-Quarter 2024 Financial Highlights and Recent Business Developments
- For the first quarter of 2024 (as compared with the first quarter of 2023):
- Worldwide revenue grew to
$101.9 million 5.8% as reported and5.6% on a constant currency basis. U.S. trial procedures decreased approximately5.1% , largely in line with the company's expectations.- Reported a first quarter 2024 net loss from operations of
$35.8 million $9.6 million
- Worldwide revenue grew to
- Nevro also announced that Christofer Christoforou has been promoted to the role of COO effective immediately. Christoforou joined the company in 2016 and most recently served as Senior Vice President, Technical Operations. In addition to his current responsibilities, which include leading the company's manufacturing processes and innovation, research and development efforts, Christoforou will have oversight of clinical and regulatory affairs and quality assurance. For Christoforou's complete biography, please visit the Leadership Team section on Nevro's corporate website.
- As previously announced on February 28, 2024, Nevro received FDA 510(k) clearance to use its sacroiliac (SI) joint fusion system, Nevro1™, without the need for a fixation screw and featuring integrated lateral transfixation.
- 24-month data from SENZA-PDN randomized controlled trial (RCT) for improved sensory function and protective sensation in the feet of patients receiving 10 kHz SCS was published in the Journal of Diabetes Science & Technology, with results demonstrating unique, disease-modifying improvement in sensory function that potentially lowers the risk of diabetes-related ulcerations and traumatic amputations.
- Nevro introduced its new solution for patients who do not have a compatible iPhone that helps increase access to the benefits of HFX iQ 10kHz Therapy™.
- Enrollment in Nevro's PDN Clinical Sensory Study ("PDN Sensory Study") now stands at 143 patients, ahead of the company's expectations. As a result of this robust enrollment combined with strong outcomes demonstrated in its SENZA-PDN RCT, the company is pausing enrollment in the PDN Sensory Study to allow for an interim primary endpoint analysis of all subjects who are randomized from this existing cohort. While the results of the analysis may indicate restarting enrollment in the future, Nevro's goal is to bring trial results to publication as soon as possible for the benefit of patients and review for inclusion in therapeutic guidelines.
First-Quarter 2024 Financial Results
Worldwide revenue for the first quarter of 2024 was
International revenue in the first quarter of 2024 was
Gross profit for the first quarter of 2024 was
Operating expenses for the first quarter of 2024 were
- a net
$3.5 million $0.7 million
Excluding the aforementioned three items, operating expenses in the first quarter of 2024 improved by
Litigation-related legal expenses were
Net loss from operations for the first quarter of 2024 was
Cash, cash equivalents and short-term investments totaled
Full-Year and Second-Quarter 2024 Financial Guidance
Based on its first-quarter 2024 performance and outlook for the remainder of this year, Nevro continues to expect its full-year 2024 worldwide revenue to be in the range of approximately
Nevro is raising its adjusted EBITDA guidance for the full-year 2024 to a range of negative
For the second quarter of 2024, the company expects worldwide revenue to be in the range of approximately
Nevro has not provided a quantitative reconciliation of forecasted adjusted EBITDA to forecasted net income (loss) within this press release because the company is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. For more information regarding the non-GAAP financial measures discussed in this press release, please see the financial table at the end of this release for GAAP to non-GAAP reconciliations, definitions and further information regarding the use of non-GAAP metrics.
An investor presentation for Nevro's first-quarter 2024 financial results is available in the "Investors" section of the company's corporate website at Events & Presentations.
Webcast and Conference Call Information
As previously announced, Nevro will host a conference call today to discuss its financial results. The call will begin at 1:30 pm PT / 4:30 pm ET. A live webcast and replay of the conference call will be available in the "Investors" section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time.
For those parties that do not have internet access, the conference call can be accessed by calling one of the below telephone numbers and providing conference ID 6973396:
| 1-888-596-4144 |
International participant dial-in number: | 1-646-968-2525 |
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in
Nevro recently added a minimally invasive treatment option for patients suffering from chronic sacroiliac joint ("SI joint") pain and now provides the most comprehensive portfolio of products in the SI joint fusion space, designed to meet the preferences of physicians and varying patient needs in order to improve outcomes and quality of life for patients.
Senza®, Senza II®, Senza Omnia®, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with HFX Coach™ support throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.
To learn more about Nevro, connect with us on LinkedIn, X, Facebook, and Instagram.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements reflecting the current beliefs and expectations of the company's management, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our second quarter and updated full-year 2024 financial guidance; our belief that the actions we have taken further position us for success; and our belief that our focus on our three key strategic pillars will improve our commercial execution and deliver significant long-term shareholder return. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth and the costs and expenses of operating our business; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to successfully integrate any additive acquisitions we may make, including our acquisition of Vyrsa Technologies; our ability to attract and retain qualified personnel; our ability to accurately forecast financial and operating results; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on February 23, 2024, as well as any reports that we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Nevro's operating results for the period ending March 31, 2024, are not necessarily indicative of the company's operating results for any future periods.
Investor and Media Contact:
Angie McCabe
Vice President, Investor Relations & Corporate Communications
angeline.mccabe@nevro.com
Nevro Corp. | ||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||
(in thousands, except share and per share data) | ||||||||
Three Months Ended | ||||||||
March 31, | ||||||||
2024 | 2023 | |||||||
(unaudited) | ||||||||
Revenue | $ | 101,899 | $ | 96,327 | ||||
Cost of revenue | 30,371 | 31,703 | ||||||
Gross profit | 71,528 | 64,624 | ||||||
Operating expenses: | ||||||||
Research and development | 14,828 | 14,755 | ||||||
Sales, general and administrative | 88,326 | 86,192 | ||||||
Amortization of intangibles | 737 | — | ||||||
Change in fair value of contingent consideration | 3,471 | — | ||||||
Total operating expenses | 107,362 | 100,947 | ||||||
Income (loss) from operations | (35,834) | (36,323) | ||||||
Other income (expense): | ||||||||
Interest income (expense), net | (2,732) | 1,665 | ||||||
Change in fair market value of warrants | 13,560 | — | ||||||
Other income (expense), net | (21) | (46) | ||||||
Income (loss) before income taxes | (25,027) | (34,704) | ||||||
Provision for income taxes | 382 | 325 | ||||||
Net income (loss) | (25,409) | (35,029) | ||||||
Changes in foreign currency translation adjustment | (255) | 506 | ||||||
Changes in unrealized gains (losses) on short-term investments | (526) | 587 | ||||||
Net change in other comprehensive income (loss) | (781) | 1,093 | ||||||
Comprehensive income (loss) | $ | (26,190) | $ | (33,936) | ||||
Net loss per share, basic and diluted | $ | (0.70) | $ | (0.98) | ||||
Weighted average shares used to compute net loss per share | 36,467,371 | 35,584,685 | ||||||
Nevro Corp. | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
(in thousands, except share and per share data) | ||||||||
March 31, | December 31, | |||||||
2024 | 2023 | |||||||
(unaudited) | ||||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 90,303 | $ | 104,217 | ||||
Short-term investments | 191,180 | 218,506 | ||||||
Accounts receivable, net | 76,918 | 79,377 | ||||||
Inventories, net | 120,789 | 118,676 | ||||||
Prepaid expenses and other current assets | 13,414 | 10,145 | ||||||
Total current assets | 492,604 | 530,921 | ||||||
Property and equipment, net | 24,708 | 24,568 | ||||||
Operating lease assets | 7,764 | 8,944 | ||||||
Goodwill | 38,324 | 38,164 | ||||||
Other intangible assets, net | 26,617 | 27,354 | ||||||
Other assets | 5,427 | 5,156 | ||||||
Restricted cash | 606 | 606 | ||||||
Total assets | $ | 596,050 | $ | 635,713 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 21,208 | $ | 22,520 | ||||
Contingent liabilities, current portion | 220 | 9,836 | ||||||
Accrued liabilities and other | 45,346 | 51,019 | ||||||
Total current liabilities | 66,774 | 83,375 | ||||||
Long-term debt | 214,763 | 211,471 | ||||||
Long-term operating lease liabilities | 3,136 | 4,634 | ||||||
Contingent liabilities, non-current portion | 15,564 | 12,257 | ||||||
Warrant liability | 15,179 | 28,739 | ||||||
Other long-term liabilities | 2,093 | 2,092 | ||||||
Total liabilities | 317,509 | 342,568 | ||||||
Stockholders' equity | ||||||||
Common stock, 37,369,746 and 37,044,390 shares issued at March 31, 2024 and December 31, 2023, respectively; 36,686,830 and 36,361,474 shares outstanding at March 31, 2024 and December 31, 2023, respectively | 36 | 36 | ||||||
Additional paid-in capital | 1,004,348 | 992,762 | ||||||
Accumulated other comprehensive loss | (1,024) | (243) | ||||||
Accumulated deficit | (724,819) | (699,410) | ||||||
Total stockholders' equity | 278,541 | 293,145 | ||||||
Total liabilities and stockholders' equity | $ | 596,050 | $ | 635,713 | ||||
Nevro Corp. | ||||||||
GAAP to Non-GAAP Adjusted EBITDA Reconciliation | ||||||||
(unaudited) | ||||||||
(in thousands) | ||||||||
The following table presents a reconciliation of GAAP net loss, as prepared in accordance with | ||||||||
Reconciliation of actual results: | ||||||||
Three Months Ended | ||||||||
March 31, | ||||||||
2024 | 2023 | |||||||
(unaudited) | ||||||||
GAAP Net Income (Loss) | $ | (25,409) | $ | (35,029) | ||||
Non-GAAP Adjustments: | ||||||||
Interest (income) expense, net | 2,732 | (1,665) | ||||||
Provision for income taxes | 382 | 325 | ||||||
Depreciation and amortization | 2,053 | 1,582 | ||||||
Stock-based compensation expense and other equity related charges | 11,674 | 13,560 | ||||||
Amortization of intangibles | 737 | — | ||||||
Change in fair value of contingent consideration | 3,471 | — | ||||||
Change in fair market value of warrants | (13,560) | — | ||||||
Litigation-related expenses | 2,801 | 3,754 | ||||||
Restructuring charges | 5,523 | 332 | ||||||
Adjusted EBITDA | $ | (9,596) | $ | (17,141) | ||||
Reconciliation of guidance: | ||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||
June 30, 2024 | December 31, 2024 | |||||||||||||||
(Low Case) | (High Case) | (Low Case) | (High Case) | |||||||||||||
GAAP Net Loss | $ | (28,500) | $ | (27,500) | $ | (94,000) | $ | (87,000) | ||||||||
Non-GAAP Adjustments | 25,000 | 25,000 | 89,000 | 89,000 | ||||||||||||
Adjusted EBITDA | $ | (3,500) | $ | (2,500) | $ | (5,000) | $ | 2,000 | ||||||||
Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the company's operating performance period over period, analyze the underlying business trends, assess performance relative to competitors and establish operational objectives.
Management believes it is important to provide investors with the same non-GAAP metrics it uses to evaluate the performance and underlying trends of the company's business operations to facilitate comparisons to its historical operating results and evaluate the effectiveness of its operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of the company's underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.
EBITDA is a non-GAAP financial measure, which is calculated by adding interest income and expense, net; provision for income taxes; and depreciation and amortization to net income. In calculating non-GAAP adjusted EBITDA, the company further adjusts for the following items:
- Stock-based compensation expense and other equity-related charges – The company excludes non-cash costs related to the company's stock-based plans, which include stock options, restricted stock units and performance-based restricted stock units as these expenses do not require cash settlement from the company.
- Amortization of intangibles – The company excludes amortization of intangibles from the acquisition of businesses.
- Change in fair value of contingent consideration – The company excludes the changes in the fair value of its contingent consideration liability.
- Change in fair market value of warrants – The company excludes the changes in the fair value of its warrant liability.
- Litigation-related expenses – The company excludes legal and professional fees as well as charges and credits associated with certain legal matters, which management considers not related to the underlying operating performance of the business.
- Restructuring charges – The company excludes charges incurred as a direct result of restructuring programs, such as salaries and other compensation-related expenses.
Full-year guidance excludes the impact of foreign currency fluctuations.
The non-GAAP financial measure should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP financial measures, as it is not prepared in accordance with
Nevro has not provided a quantitative reconciliation of forecasted adjusted EBITDA to forecasted net income (loss) within this press release because the company is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items include, but are not limited to, stock-based compensation expenses, amortization of intangibles, change in fair value of contingent consideration, change in fair value of warrants, and litigation-related expenses.
Amounts may not add due to rounding.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-reports-first-quarter-2024-financial-results-302138733.html
SOURCE Nevro Corp.
FAQ
What were Nevro's worldwide revenue and adjusted EBITDA for the first quarter of 2024?
Who was promoted to the Chief Operating Officer role at Nevro?
What is Nevro's full-year revenue guidance for 2024?
What is Nevro's adjusted EBITDA guidance for the full-year 2024?
What financial changes did Nevro experience in the first quarter of 2024?
